Snake Venom Peptide Outperforms Standard BNP in Protecting Hearts After Heart Attack in Mice

Mice underwent coronary artery ligation followed by reperfusion to model heart attack and ischemia-reperfusion injury. Animals received a single injection of either L2, BNP, or no treatment. Researchers measured infarct size, fibrosis, inflammatory cell infiltration (including M1 vs. M2 macrophage subsets), endothelial cell density, and cardiomyocyte density in the injured heart tissue. Results were compared across all treatment groups.

Heart attacks cause massive tissue damage partly through the inflammatory response that follows blood flow restoration. Current therapies focus on reopening blocked arteries but do little to manage this harmful inflammation. L2's ability to shift immune cells from a destructive (M1) to a healing (M2) state while preserving heart muscle and blood vessels represents a fundamentally different protective mechanism — one that could complement existing treatments and improve long-term outcomes after heart attack.

Snake venoms are a rich source of bioactive peptides, and this study demonstrates how venom-derived molecules can be repurposed as potential therapeutics. Natriuretic peptides already play important roles in heart failure treatment, and L2's superior anti-inflammatory properties compared to mammalian BNP suggest that evolution has optimized venom peptides in ways that could benefit human medicine. This work contributes to the growing field of venom-based drug discovery.

This is a preclinical mouse study, and results may not translate directly to humans. Sample sizes were not specified in the abstract. The study used a single injection, so optimal dosing regimens for sustained protection are unknown. The exact mechanism by which L2 uniquely promotes M2 macrophage polarization was not fully elucidated. Long-term cardiac functional outcomes beyond the acute and subacute phases were not reported.